Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT)Apr 26, 2023
Feb 28, 2023FDA Grants Orphan Drug Designation to Ymmunobio’s CEACAM Antibody for the Treatment of Liver CancerYmmunobio developed CEACAM antibody YB-200 for the treatment of hepatocellular carcinoma (HCC) RIEHEN, SWITZERLAND, February 28, 2023 ─...
Feb 16, 2023Ymmunobio Appoints Dr. Caroline Germa to Board of DirectorsMedical oncologist & CMO at Transcenta joins the board of growing biotech company February 16, 2023 ─ Ymmunobio, a preclinical stage...
Feb 8, 2023Ymmunobio Appoints Angela S. Gibbs as Chief Business OfficerGrowing preclinical-stage biotech company adds to executive team RIEHEN, SWITZERLAND, February 8, 2023 ─ Ymmunobio AG, a preclinical...